Takeda boosts sales of Lundbeck-developed drug in H1 2021

Takeda's reported revenue, including the sales of the antidepressant Trintellix/Brintellix, which Takeda and Lundbeck market in a collaboration in the US and Japan, grew by 12.8 percent in the first half of the fiscal year.

In the months spanning April to September, which make up the first half of the staggered fiscal year of 2021, Takeda's revenue has gone up by 12.8 percent compared to the prior Covid-19-affected year, it reports in a press release on Thursday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading